Mankind Pharma Limited
Mankind Pharma Limited demonstrates strong profitability and capital allocation, supported by robust revenue and net profit growth over the long term. However, recent trends show declining ROE and ROCE, alongside fluctuating free cash flow. The company maintains a moderate debt profile but faces challenges with current liquidity. The current valuation indicates the stock is trading above its calculated fair value, suggesting a premium. Overall, while the business exhibits solid operational metrics, attention should be paid to the recent efficiency and cash flow trends.
Business Performance (CAGR)
Valuation Snapshot
Financial Health
Profitability Metrics
Cash Flow Intelligence
Intrinsic Value
PremiumEstimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
Mankind Pharma presents a strong operational base with impressive historical growth and capital allocation. However, recent declines in capital efficiency metrics (ROE, ROCE), volatile free cash flow, and a low current ratio necessitate careful monitoring. The current market valuation appears to be at a premium to its calculated intrinsic value, suggesting that the market has factored in future growth potential.
- Strong historical revenue and net profit growth.
- Excellent capital allocation efficiency as indicated by a high score.
- Robust operating cash flow generation, significantly exceeding net profits.
- Moderate debt levels with good interest coverage.
Balance Sheet
Mankind Pharma Limited has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
Capacity to fund growth, withstand downturns and return capital.
- Mankind Pharma Limited has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
- Balance sheet is functional but shows no standout strengths
- Tight short-term liquidity cushion
- Long working capital cycle
- Slow book value compounding